.png){kind=icon}
.png){kind=icon}
Return
Type 1 diabetes
.png){kind=icon}
OA
AI
DOI：10.1016/S0140-6736(13)60591-7.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes has grown substantially, particularly with regard to disease prediction and heterogeneity, pancreatic pathology, and epidemiology. Technological improvements in insulin pumps and continuous glucose monitors help patients with type 1 diabetes manage the challenge of lifelong insulin administration. Agents that show promise for averting debilitating disease-associated complications have also been identifi ed. However, despite broad organisational, intellectual, and fi scal investments, no means for preventing or curing type 1 diabetes exists, and, globally, the quality of diabetes management remains uneven. This Seminar discusses current progress in epidemiology, pathology, diagnosis, and treatment of type 1 diabetes, and prospects for an improved future for individuals with this disease.
Keywords:
STEM-CELL TRANSPLANTATION
INSULIN-PUMP THERAPY
DOUBLE-BLIND
C-PEPTIDE
COMPLICATIONS-TRIAL/EPIDEMIOLOGY
CARDIOVASCULAR-DISEASE
NOCTURNAL HYPOGLYCEMIA
GENETIC SUSCEPTIBILITY
ISLET TRANSPLANTATION
ARTIFICIAL PANCREAS
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
